Impact of somatic mutations and transcriptomic alterations on cancer aneuploidy.


Journal

Biomedical research (Tokyo, Japan)
ISSN: 1880-313X
Titre abrégé: Biomed Res
Pays: Japan
ID NLM: 8100317

Informations de publication

Date de publication:
2023
Historique:
medline: 31 10 2023
pubmed: 2 10 2023
entrez: 1 10 2023
Statut: ppublish

Résumé

Aneuploidy has been recognized as one of hallmark of tumorigenesis since the early 20th century. Recent developments in structural variation analysis in the human genome have revealed the diversity of aneuploidy in cancer. However, the effects of gene mutation and expression in tumors on aneuploidy remain poorly understood. Here, we performed whole exome analysis of over 5,000 Japanese cancer cases and investigated the impact of somatic mutations and gene expression alterations on aneuploidy. First, we evaluated tumor content and genomic alterations that could influence aneuploidy. Next, we compared the aneuploidy frequency in 18 cancer types and observed that TP53 mutations were associated with the aneuploidy on specific chromosomes in colorectal and gastric cancers. Finally, we used expression analysis to isolate pathways involved in aneuploidy accumulation from tumors without TP53 mutations. Chromosomal instability and cell cycle aberration were associated with aneuploidy in TP53 wild-type tumors, and 26 commonly upregulated genes were identified in aneuploidy-high solid tumors without TP53 mutations. Among them, two cancer-related genes (CENPA and PBK) were involved in aneuploidy. Our integrated analysis revealed that both TP53 mutations and transcriptomic alterations independent of somatic mutations affect aneuploidy accumulation. Our findings will facilitate further understanding of diverse aneuploidies in the tumorigenesis.

Identifiants

pubmed: 37779031
doi: 10.2220/biomedres.44.187
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

187-197

Auteurs

Keiichi Hatakeyama (K)

Cancer Multiomics Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Takeshi Nagashima (T)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.
SRL Inc., Shinjuku-ku, Tokyo 163-0409 Japan.

Keiichi Ohshima (K)

Medical Genetics Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Sumiko Ohnami (S)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Shumpei Ohnami (S)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Yuji Shimoda (Y)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Akane Naruoka (A)

Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Koji Maruyama (K)

Experimental Animal Facility, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Akira Iizuka (A)

Immunotheraphy Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Tadashi Ashizawa (T)

Immunotheraphy Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Hirotsugu Kenmotsu (H)

Division of Thoracic Oncology, Shizuoka Cancer Center Hos- pital, Sunto-gun, Shizuoka, Japan.

Tohru Mochizuki (T)

Medical Genetics Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Kenichi Urakami (K)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Yasuto Akiyama (Y)

Immunotheraphy Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka 411-8777 Japan.

Ken Yamaguchi (K)

Shizuoka Cancer Center, Sunto-gun, Shizuoka 411-8777 Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH